Cytoplasmic superoxide causes bone fragility owing to low-turnover osteoporosis and impaired collagen cross-linking.
The aging process correlates with the accumulation of cellular and tissue damage caused by oxidative stress. Although previous studies have suggested that oxidative stress plays a pathologic role in the development of bone fragility, little direct evidence has been found. In order to investigate the pathologic significance of oxidative stress in bones, we analyzed the bone tissue of mice deficient in cytoplasmic copper/zinc superoxide dismutase (CuZn-SOD, encoded by the Sod1 gene; Sod1(-/-)). In this study, we showed for the first time that in vivo cytoplasmic superoxide caused a distinct weakness in bone stiffness and decreased BMD, aging-like changes in collagen cross-linking, and transcriptional alterations in the genes associated with osteogenesis. We also showed that the surface areas of osteoblasts and osteoclasts were decreased significantly in the lumbar vertebrae of Sod1(-/-) mice, indicating the occurrence of low-turnover osteopenia. In vitro experiments demonstrated that intracellular oxidative stress induced cell death and reduced the proliferation in primary osteoblasts but not in osteoclasts, indicating that impaired osteoblast viability caused the decrease in osteoblast number and suppressed RANKL/M-CSF osteoclastogenic signaling in bone. Furthermore, treatment with an antioxidant, vitamin C, effectively improved bone fragility and osteoblastic survival. These results imply that intracellular redox imbalance caused by SOD1 deficiency plays a pivotal role in the development and progression of bone fragility both in vivo and in vitro. We herein present a valuable model for investigating the effects of oxidative stress on bone fragility in order to develop suitable therapeutic interventions.
Molecular Gerontology, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo, Japan.
Hidetoshi
H
Nojiri
Yoshitomo
Y
Saita
Daichi
D
Morikawa
Keiji
K
Kobayashi
Chizuru
C
Tsuda
Tsuyoshi
T
Miyazaki
Mitsuru
M
Saito
Keishi
K
Marumo
Ikuho
I
Yonezawa
Kazuo
K
Kaneko
Takuji
T
Shirasawa
Takahiko
T
Shimizu
D000375:Aging / Q000187:drug effects / Q000473:pathology; D000818:Animals; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000494:pharmacology; D001862:Bone Resorption / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D002452:Cell Count; D002470:Cell Survival / Q000187:drug effects; D003094:Collagen / Q000378:metabolism*; D003432:Cross-Linking Reagents / Q000378:metabolism*; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism*; D016173:Macrophage Colony-Stimulating Factor / Q000378:metabolism; D051379:Mice; D009929:Organ Size / Q000187:drug effects; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000150:complications / Q000378:metabolism* / Q000473:pathology* / Q000503:physiopathology; D010084:Oxidation-Reduction / Q000187:drug effects; D010641:Phenotype; D053245:RANK Ligand / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013482:Superoxide Dismutase / Q000172:deficiency / Q000378:metabolism; D013481:Superoxides / Q000378:metabolism*
D003432:Cross-Linking Reagents; D053245:RANK Ligand; D013481:Superoxides; D016173:Macrophage Colony-Stimulating Factor; D003094:Collagen; D013482:Superoxide Dismutase; D001205:Ascorbic Acid